Shanghai Pharma sees controlling shareholder's ownership structure consolidate

Shanghai Pharmaceuticals Holding Co. announced a voluntary change in shareholder interest following an equity transfer agreement on September 24, 2025. Shanghai Shangshi Yangtze River Delta agreed to transfer its 40% equity interest in Shanghai Pharmaceutical (Group) Co., Ltd. to Shanghai Shangshi (Group) Co., Ltd. for 6,721.5148 million yuan.

Before the transfer, Shanghai Shangshi (Group) Co., Ltd. held 60% of Shanghai Pharmaceutical (Group). Following the transfer, Shanghai Shangshi (Group) Co., Ltd. now holds 100% of Shanghai Pharmaceutical (Group).

Shanghai Pharmaceutical (Group) is a controlling shareholder of Shanghai Pharmaceuticals, directly holding 716,516,039 A shares, representing 19.322% of the company's total share capital. Prior to the transfer, Shanghai Shangshi Yangtze River Delta indirectly held 286,606,415.6 A shares of the company, a 7.729% shareholding. Post-transfer, Shanghai Shangshi Yangtze River Delta no longer holds any equity interest in Shanghai Pharmaceutical (Group) or the company. This change does not trigger a mandatory tender offer or alter the company's controlling shareholders or de facto controller.